Corneal Infection Therapy with Topical Bacteriophage Administration



Ali Fadlallah*, 1, 3, Elias Chelala4, Jean-Marc Legeais2, 3
1 Pierre et Marie Curie University, Sorbonne Universities, Paris, France
2 Paris Descartes University, Paris, France
3 Hôtel Dieu de Paris Hospital, Paris, France
4 Saint-Joseph university, Faculty of Medicine, Beirut, Lebanon


Article Metrics

CrossRef Citations:
3
Total Statistics:

Full-Text HTML Views: 387
Abstract HTML Views: 278
PDF Downloads: 85
Total Views/Downloads: 750
Unique Statistics:

Full-Text HTML Views: 166
Abstract HTML Views: 125
PDF Downloads: 54
Total Views/Downloads: 345



© Fadlallah et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the (https://creativecommons.org/licenses/by/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Hôtel Dieu de Paris Hospital, 1 Parvis Notre-Dame, 75004, Paris, France; E-mail: Fadlallahmd@gmail.com


Abstract

Staphylococcus aureus is a major pathogen in bacterial keratitis, a vision-threatening disease. Although the incidence of S. aureus keratitis varies worldwide, the increasing trend of resistance to certain antibiotics makes this condition an important, global, healthcare concern. We report the case of a 65-year-old woman with nosocomial left-eye corneal abscess and interstitial keratitis.The patient then undergo topical Phage therapy with successful results.

Keywords: VRSA, Interstitial Keratitis, phage therapy.